ADVB — ADVANCED BIOMED Income Statement
0.000.00%
Last trade - 00:00- $10.40m
- $7.49m
Annual income statement for ADVANCED BIOMED, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.84 | 3.99 | 3.22 | 2.54 | 3.02 |
| Operating Profit | -1.84 | -3.99 | -3.22 | -2.54 | -3.02 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.84 | -4.03 | -3.73 | -2.78 | -3.26 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.84 | -4.03 | -3.73 | -2.78 | -3.26 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.84 | -4.03 | -3.73 | -2.78 | -3.26 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.84 | -4.03 | -3.73 | -2.78 | -3.26 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.085 | -0.111 | -0.166 | -0.129 | -0.159 |